New DOJ Healthcare Fraud Task Force: What It Is and What It Means Legally

The Task Force's Operational Blueprint: Why This Is Different From Prior Enforcement Efforts

In my 25 years as a federal prosecutor, I have witnessed numerous DOJ task forces come and go, but the newly established DOJ Healthcare Fraud Task Force represents a fundamental shift in enforcement architecture that demands immediate attention from every healthcare provider, executive, and compliance professional in this country. The Task Force is not merely a rebranding of the existing Health Care Fraud Prevention and Enforcement Action Team (HEAT) or the Medicare Fraud Strike Force; rather, it is a permanent, statutorily-grounded entity operating under the direct supervision of the Deputy Attorney General with an explicit mandate to coordinate all federal healthcare fraud investigations, prosecutions, and civil enforcement actions nationwide. The enabling memorandum specifically references the authority granted under 28 U.S.C. § 509 (the Attorney General's supervisory powers) and 18 U.S.C. § 1347 to create what the DOJ describes as "a unified command structure" that eliminates the traditional silos between criminal prosecutors, civil litigators, and administrative enforcement personnel. What this means practically is that a provider who previously might have faced only a civil False Claims Act investigation for billing irregularities now faces the very real prospect of a simultaneous criminal grand jury investigation, civil discovery requests, and an administrative exclusion proceeding—all coordinated by a single lead prosecutor who has visibility into every aspect of the government's case.

The Task Force has been allocated substantial new resources, including 120 additional FBI agents detailed exclusively to healthcare fraud matters, 45 new Assistant U.S. Attorneys with specialized healthcare fraud training, and a dedicated Data Analytics Unit housed within the DOJ's Executive Office for U.S. Attorneys. This unit is equipped with proprietary software that ingests raw claims data from Medicare, Medicaid, and the top 20 private insurers on a rolling 90-day basis, allowing the government to identify billing anomalies, referral pattern irregularities, and outlier prescribing practices in near real-time. During my tenure as a federal prosecutor, we relied heavily on whistleblower complaints and manual audits to identify potential fraud; today, the Task Force's data analytics team can flag a physician for statistical deviation in evaluation and management coding within weeks of the claims being submitted, often before the provider has even received payment. The legal significance of this operational shift cannot be overstated: the government no longer needs a credible whistleblower or a lengthy audit cycle to initiate a criminal investigation, and the sheer volume of data available means that virtually every provider will, at some point, appear as an outlier on some metric, creating a dangerous "needle in a haystack" problem where innocent billing variations are treated as presumptive evidence of fraudulent intent.

Perhaps most concerning from a defense perspective is the Task Force's explicit authorization to use "parallel proceeding" techniques codified in the Attorney General's memorandum, which permits criminal prosecutors to share grand jury materials with civil attorneys under Federal Rule of Criminal Procedure 6(e) without seeking separate court approval for each disclosure. This means that statements made by a provider during a civil False Claims Act investigation, including deposition testimony and document productions, can now be directly funneled into a criminal grand jury proceeding without the provider's knowledge or consent, effectively eliminating the traditional firewall between civil and criminal enforcement. I have personally represented clients who were lulled into thinking they were merely dealing with an overpayment issue under 42 U.S.C. § 1320a-7k(d), only to discover months later that their civil cooperation had produced a detailed roadmap for a criminal indictment. The Task Force's operational blueprint makes this scenario the default rather than the exception, and any provider who receives a civil investigative demand (CID) from HHS-OIG or a subpoena from the U.S. Attorney's Office must immediately assume that a parallel criminal investigation is already underway.

Statutory Exposure Under the New Enforcement Regime: Beyond the Traditional Fraud Statutes

The legal landscape that the Task Force will enforce is far broader than most healthcare providers realize, extending well beyond the familiar Health Care Fraud Statute (18 U.S.C. § 1347) and the False Claims Act (31 U.S.C. § 3729) into a web of ancillary criminal statutes that prosecutors are increasingly using to secure convictions and enhance sentences. The Task Force's training materials, which I have reviewed in connection with several ongoing representations, specifically emphasize the use of the Major Fraud Act (18 U.S.C. § 1031) in healthcare cases involving federal contracts, the Money Laundering Control Act (18 U.S.C. § 1956 and § 1957) for financial transactions derived from fraudulent billing, and the Travel Act (18 U.S.C. § 1952) for interstate conduct in furtherance of unlawful activity. In my experience, prosecutors now routinely charge a single course of conduct under multiple statutes to maximize sentencing exposure, and the Task Force's coordinated approach makes it easier than ever to stack charges that carry consecutive rather than concurrent sentences. For example, a physician who submits false claims to Medicare and then deposits the proceeds into a business bank account could face separate counts for healthcare fraud (10 years), false statements (5 years under 18 U.S.C. § 1001), money laundering (10 years under 18 U.S.C. § 1957), and conspiracy (5 years under 18 U.S.C. § 371), yielding a potential statutory maximum of 30 years for conduct that might previously have been charged as a single healthcare fraud count.

The Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)) remains the single most dangerous statute for healthcare providers because it criminalizes not just intentional fraud but also arrangements that have the "purpose" of inducing referrals, regardless of whether any actual harm to patients or the government occurred. The Task Force has specifically announced that it will prioritize "value-based" arrangements, management services agreements, and medical director contracts that may appear legitimate on their face but contain compensation structures that vary with the volume or value of referrals. The Department of Health and Human Services' Office of Inspector General (HHS-OIG) has issued advisory opinions and safe harbor regulations under 42 C.F.R. § 1001.952 that define permissible arrangements, but the Task Force's prosecutors are not bound by these safe harbors in the criminal context and may argue that even technically compliant arrangements violate the statute if the government can prove improper intent. I have seen cases where a hospital's medical directorship agreement with a referring physician, paying fair market value as determined by an independent compensation consultant, still resulted in criminal charges because the government argued that the timing of the payments and the physician's referral patterns demonstrated a "quid pro quo" arrangement. The Task Force's data analytics capabilities make it trivially easy to identify physicians whose referral volumes increase after entering into such agreements, and the government will almost certainly use this data to support search warrant affidavits and grand jury subpoenas.

Beyond the traditional fraud and kickback statutes, the Task Force is also aggressively pursuing charges under the Controlled Substances Act (21 U.S.C. § 841 and § 846) for healthcare providers involved in prescribing practices that the government deems to be outside the usual course of professional practice. This is not limited to the so-called "pill mill" cases that dominated the opioid crisis prosecutions; rather, the Task Force has expanded its focus to include any prescribing pattern that deviates from CDC guidelines or state medical board standards, even for non-opioid medications. During my years as a prosecutor, I observed that charging a physician under the Controlled Substances Act carries significant advantages for the government because it allows for asset forfeiture under 21 U.S.C. § 853, mandatory minimum sentences in certain circumstances, and the ability to use patient testimony to establish that prescriptions were issued without a legitimate medical purpose. The intersection of healthcare fraud and controlled substance violations creates a particularly dangerous legal exposure because the government can argue that any prescribing outside the standard of care is presumptively fraudulent, shifting the burden to the provider to prove that their clinical judgment was reasonable. The Task Force's memorandum explicitly identifies "telemedicine prescribing schemes" and "compounding pharmacy arrangements" as priority targets, and I am currently seeing a surge in grand jury subpoenas directed at physicians who prescribed GLP-1 agonists, testosterone replacement therapy, and other high-demand medications through virtual consultations.

Practical Defense Imperatives: What Every Healthcare Entity Must Do Now to Survive a Task Force Investigation

Based on my extensive experience representing healthcare providers and entities under investigation, the single most critical step any organization can take in response to the Task Force's formation is to conduct a comprehensive "parallel proceeding vulnerability assessment" that evaluates every revenue stream, referral relationship, and billing practice through the lens of how the government's data analytics team would view that same information. This assessment must go beyond traditional compliance audits that merely check for technical compliance with billing codes and documentation requirements; it must proactively identify any statistical outlier patterns in your claims data that could trigger the Task Force's algorithms, and then develop contemporaneous documentation that explains the legitimate clinical or business reasons for those patterns. For example, if your practice has a higher-than-average rate of level 5 evaluation and management codes (CPT 99285) compared to your peers, you need to have a written clinical justification for each such encounter that demonstrates medical necessity, not just a checkbox on a billing sheet. I have represented practices where the government's expert witness testified that statistical deviation alone was sufficient to establish "conscious avoidance" of the truth, and the only effective defense was to produce detailed medical records showing that each patient actually required the higher level of service. The Task Force's data analytics mandate makes this proactive documentation strategy not just advisable but absolutely essential for survival.

Every healthcare entity that receives federal funds should immediately review and, where necessary, revise its corporate compliance program to specifically address the Task Force's enforcement priorities, including the creation of a "Task Force Response Protocol" that designates a specific attorney (preferably with federal criminal defense experience) as the single point of contact for any government inquiry. The Federal Sentencing Guidelines (U.S.S.G. § 8B2.1) require that an effective compliance program include "reasonable steps to respond to and prevent further similar offenses" upon detection of any potential violation, and the Task Force will scrutinize whether your organization took immediate corrective action upon discovering an issue. In my practice, I have seen too many providers make the catastrophic mistake of conducting an internal investigation without involving counsel, only to have their internal findings used against them under the "adoptive admission" theory or the "business records" exception to the hearsay rule. The attorney-client privilege and the work product doctrine (codified in Federal Rule of Civil Procedure 26(b)(3)) are your most powerful defenses against the government's discovery of your internal assessments, but these protections are waived if you share the results of your investigation with third parties, including insurers, billing companies, or even your own board members without proper legal guidance. The Task Force's prosecutors are specifically trained to identify and exploit any waiver of privilege, and I have seen entire cases built around a single email that a compliance officer sent to a vendor discussing potential billing errors.

Perhaps the most important defensive measure that providers consistently overlook is the strategic use of the "pre-indictment" period to engage with the government on terms that preserve your legal rights while potentially avoiding criminal charges altogether. The Task Force's memorandum explicitly encourages prosecutors to consider "alternatives to prosecution" such as deferred prosecution agreements (DPAs), non-prosecution agreements (NPAs), and pre-trial diversion programs, but these options are only available to entities and individuals who proactively engage the government before an indictment is returned. In my experience, the window for such engagement is extremely narrow—typically 60 to 90 days from the date you receive your first subpoena or civil investigative demand—and any delay in retaining experienced counsel can result in the government taking an adversarial posture that forecloses these alternatives. The Task Force's prosecutors are evaluated based on conviction rates and recovery amounts, so they have little incentive to offer favorable resolutions to defendants who appear unrepresented or unprepared. However, when you demonstrate through a comprehensive "defense presentation" that your organization has robust compliance controls, has taken immediate corrective action, and is willing to cooperate fully with the government's investigation, I have seen prosecutors recommend DPAs that allow entities to avoid criminal conviction and the mandatory exclusion from federal programs that would otherwise follow under 42 U.S.C. § 1320a-7(a). The key is to act before the government has invested significant resources in building a case against you, and that means retaining counsel at the first sign of any inquiry, not after a grand jury has already returned an indictment.

FAQ: Critical Questions About the DOJ Healthcare Fraud Task Force

Q: What specific types of conduct is the Task Force prioritizing in its first year of operation, and how does this differ from prior enforcement priorities?
A: Based on the Task Force's operational plan and my discussions with former colleagues still in the DOJ, the enforcement priorities for the first year focus on three specific areas: (1) telemedicine fraud, particularly schemes involving remote prescribing of high-cost medications and durable medical equipment, where the government alleges that virtual consultations were used to circumvent legitimate doctor-patient relationships; (2) "add-on" billing practices in the hospital setting, including the unbundling of laboratory tests, the upcoding of observation services to inpatient admissions, and the separate billing of services that should be included in a global surgical package under Medicare's physician fee schedule; and (3) private equity-owned healthcare entities, where the Task Force is specifically targeting management services agreements, professional services agreements, and other contractual arrangements that the government believes are designed to circumvent the Stark Law and Anti-Kickback Statute while maximizing revenue. What makes these priorities different from prior enforcement efforts is the Task Force's systematic use of data analytics to identify targets before any whistleblower complaint is filed, and its explicit authorization to pursue "pattern or practice" cases that seek injunctive relief against entire corporate entities rather than just individual wrongdoers.

Q: If I receive a subpoena or civil investigative demand from HHS-OIG or the U.S. Attorney's Office, what are the first three things I should do to protect my legal rights?
A: The first and most critical step is to immediately retain experienced federal criminal defense counsel who specializes in healthcare fraud matters, and I cannot emphasize enough that this is not the time to rely on your general corporate counsel or a civil litigator who has never handled a federal criminal investigation. The second step is to issue a written litigation hold to every employee, contractor, and agent who may have relevant documents or information, specifically instructing them to preserve all electronic communications, billing records, medical records, and financial documents without destroying, altering, or deleting anything—even if your standard document retention policy would otherwise permit destruction. The third step is to conduct a "privilege-protected" internal review with your attorney to identify the scope of the potential exposure, including any documents or communications that could be construed as evidence of intent to defraud, and to prepare a response strategy that preserves your right to assert the Fifth Amendment privilege against self-incrimination if the government seeks to interview you or your employees. I have seen providers make the fatal error of trying to "cooperate" with the government by voluntarily producing documents and submitting to interviews without counsel present, only to discover that their cooperation was used to build a criminal case against them under the theory that any inconsistency in their statements constituted proof of fraudulent intent under 18 U.S.C. § 1001.

If you are a healthcare provider, executive, or compliance professional who has received any government inquiry, or if you simply want to ensure your organization is prepared for the Task Force's enhanced enforcement environment, I encourage you to contact our firm immediately. We have extensive experience representing clients in parallel criminal, civil, and administrative proceedings, and we can help you conduct the vulnerability assessment and implement the defensive measures necessary to protect your license, your practice, and your freedom. Time is not on your side—every day that passes without a proactive defense strategy increases the likelihood that the government's data analytics will flag your organization as a target. Call our office today to schedule a confidential consultation.